SLLN-15 is an oral active, selective and potent enhancer of autophagy. SLLN-15 activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) [1].

Treatment with SLLN-15 at concentrations of 0, 1, 5, 10, and 25 µM for 24 hours significantly decreases the viability of breast cancer cells in a dose-dependent manner, demonstrating its potency against these cells [1]. Similarly, SLLN-15 administered at 100 nM and 1000 nM for 7 days effectively inhibits the colony formation abilities across various breast cancer cell lines, including TNBC (triple-negative breast cancer) lines like MDA-MB-231 and BT-20, without discrimination [1]. SLLN-15 exercises its anti-proliferative effects on TNBC cell lines MDA-MB-231 and BT-20, predominantly through the induction of autophagy and autophagic flux. This action corresponds with a specific inhibition of the AKT-MTOR signaling pathway, further establishing its targeted mechanism in reducing cell viability and proliferation in these cancer cells.

SLLN-15 (30mg/kg, PO, 3 times a week) effectively suppresses the growth of triple-negative breast cancer (TNBC) and hinders TNBC cell progression to metastases in animal models, demonstrating significant anti-cancer and anti-metastatic properties in mice with TNBC. Utilizing BALB/c mice or SCID mice implanted with mouse mammary carcinoma 4T1 cells and human breast adenocarcinoma MDA-MB-231 cells (1 X 10^6 cells/each mouse) [1], SLLN-15 was administered orally at a dosage of 30mg/kg, three times weekly for 40 days. Results showed a marked slowdown in tumor allograft growth and a notable reduction in the number of lung metastases when compared to control groups [1].